The Journal of Pharmacology and Experimental Therapeutics has retracted this article. In September 2024, Athira Pharmas LIFT-AD trial of fosgonimetona clinical derivative of Dihexafailed to meet primary and secondary endpoints in 312 mild-to-moderate Alzheimers patients
*Correspondence: Qi Zhao, [email protected]
Rated 4.9 out of 5 based on 14 customer ratings (14 customer reviews) 99.85% purity Lyophilized powder 190.00 AED Certificate of Analysis 99.85% Tested purity 99.85% Measured content 48.74mg Test date 28/05/2026 Current batch NVCU50-01052026 Issued by an accredited independent laboratory and tied to this peptide
Its not like the guy whos on 28 nM is on too much or the guy whos on a level of eight is on too little because thats where his body is set to. Prof McLachlan You can think of it like height perfectly healthy men can be 165cm or 205 cm, its just where you sit on the reference range
Sequence identity, chromatographic purity, net peptide content, sterility, safety and legal status are six different questions
